AOD-9604 vs Exenatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Also: Byetta, Bydureon
The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Key Comparison Insights
- Exenatide is FDA approved, while AOD-9604 remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to AOD-9604 (Human Trials).
Detailed Comparison
| Attribute | AOD-9604 | Exenatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | AOD-9604 mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. It stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells. | Exenatide is a synthetic version of exendin-4 from Gila monster venom. It shares 53% homology with human GLP-1 and resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | 5-10 mcg twice daily or 2 mg weekly Twice daily (IR) or once weekly (ER) |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection |
| Typical Duration | 12-24 weeks in studies | Long-term / chronic use |
| Best Time to Take | Morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical trials showed modest weight loss effects but failed to meet primary endpoints for FDA approval. Some studies show cartilage regeneration potential. Research demonstrates safety profile similar to placebo with no significant GH-like side effects. | First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels. |
Frequently Asked Questions: AOD-9604 vs Exenatide
What is the difference between AOD-9604 and Exenatide?
AOD-9604 is a weight loss peptide that a modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full gh. Exenatide is a weight loss peptide that the first glp-1 receptor agonist approved for diabetes. derived from gila monster saliva. available in twice-daily and weekly formulations. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or Exenatide?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Exenatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and Exenatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Exenatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of AOD-9604 and Exenatide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.